xpeer logo
© Xpeer 2026 All rights reserved
Privacy Policy - Terms of Use - Help

Register now for free!

Over 100,000 doctors have already joined Xpeer — register now to find out why, and get instant access to this course and many more.

I already have an account
Course Preview

Transforming Endometrial Cancer Care

4.5

Accredited (Credits: 1.5)
Free
1h 41min
Audio: English

Synopsis

This non-promotional educational webinar presents new data on the treatment of endometrial cancer, explained by a panel of experts. First, the latest clinical evidence, the unmet medical needs, and the outlook for the future are presented to the audience in a factual manner. In the second part, patient cases are discussed to illustrate practical implementation. The expert panel comments on the cases, shares experiences and opinions, and explores the practical implications and limitations of the data while addressing remaining open questions. This approach brings theory close to everyday clinical practice and may help inform treatment decisions for your patients.

This activity is supported by an independent support grant from MSD

Accreditation

This course is accredited with 1.5 ECMEC credits valid in 26 countries. To claim your credits take the evaluation (satisfaction survey and evaluation questionnaire). You have 3 attempts for the evaluation. You need to pass the evaluation with a sufficient score to validate the course. Your diploma is issued instantaneously and sent to your email.

See more information on the accreditation at: Accreditation

Duration

1h 41min

Target audience

Obstetrics, Gynecology, General practice, Family medicine, Oncology, Gynecologic oncology, General surgical oncology

Authors

Prof. Isabelle Ray-Coquard

Prof. Isabelle Ray-Coquard is a medical oncologist at Centre Léon Bérard, Lyon, France, specializing in gynecological cancers and sarcomas. She is a leader in translational oncology research and has held prominent leadership roles within international gynecologic oncology research networks.

Conflicts of interests statement:

Prof. Dr. Isabelle ​Ray-Coquard​ received honoraria (self) from: Agenus, Blueprint, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche, GSK, MSD, Deciphera, Mersena, Merck Sereno, Novartis, Amgen, Macrogenics, Tesaro and Clovis; Honoraria (institution) from GSK, MSD, Roche and BMS; Advisory/consulting fees from Abbvie, Agenus, Advaxis, BMS, ESAÏ, Daichi, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche/Genentech, GSK, MSD, Deciphera, Mersana, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; research grant/funding (self) from MSD, Roche and BMS; Research grant/funding (institution) from MSD, Roche, BMS, Novartis, Astra Zeneca and Merck Sereno; Travel support from Roche, MSD, AstraZeneca and GSK.

Testimonials

“Excellent platform to stay up to date and keep learning throughout your professional career. I recommend it to all my colleagues.”

Omar I. onTrustpilot

Spain

“Xpeer is a magnificent platform for healthcare professionals, where you can gain knowledge from a scientific and highly up-to-date perspective across various medical specialties.”

Wil A. onTrustpilot

Netherlands

“I've taken several courses on Xpeer and they've been very useful. The format is very dynamic, allowing you to watch the videos in your free time since they're no longer than 15 minutes. The topics are very current.”

Francisco P. onTrustpilot

Spain

Read more reviews onTrustpilot

FAQs

What you will learn

Before you begin

  • Pre-course assessment: please complete to help us personalize your learning experience

Introduction

  • Introduction

Critical view on the new data in endometrial cancer

  • The recurrent setting
  • Recent clinical data in the front line setting
  • Efficacy in specific patient populations
  • Role of PARP-I in pMMR
  • Duration of treatment
  • Can chemotherapy be replaced
  • Post-Immunotherapy
  • ADC’s in clinical development
  • Conclusions

Using evidence to navigate difficult routine clinical dilemmas

  • Patient case 1: the case illustrates the heterogeneity of the NSMP subgroup and the prognostic relevance of tumour grade and ER status.
  • Patient case 2: the case is used to discuss adjuvant treatment in p53-abnormal high-risk EC.
  • Patient case 3: this case illustrates the importance of molecular profiling.

Closing and acknowledgments

  • Closing and acknowledgments

Accreditation - Evaluation

  • Satisfaction survey
  • Multiple-choice test

Register now for free!

Over 100,000 doctors have already joined Xpeer — register now to find out why, and get instant access to this course and many more.

I already have an account